Cassandra L Pattinson1, Pashtun Shahim, Patricia Taylor, Kerri Dunbar, Vivian A Guedes, Vida Motamedi, Chen Lai, Christina Devoto, Jordan Peyer, Michael J Roy, Jessica M Gill. 1. National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland (Drs Pattinson, Guedes, Lai, and Gill, Ms Motamedi, and Messrs Devoto and Peyer); Center for Neuroscience and Regenerative Medicine, Rockville, Maryland (Dr Shahim and Mss Taylor and Dunbar); National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (Dr Shahim); Henry M. Jackson Foundation, Bethesda, Maryland (Mss Taylor and Dunbar and Dr Roy); and Uniformed Services University of the Health Sciences, Department of Medicine, Bethesda, Maryland (Dr Roy).
Abstract
OBJECTIVE: To understand the relationships between traumatic brain injury (TBI), blood biomarkers, and symptoms of posttraumatic stress disorder (PTSD), depression, and postconcussive syndrome symptoms. DESIGN: Cross-sectional cohort study using multivariate analyses. PARTICIPANTS: One hundred nine military personnel and veterans, both with and without a history of TBI. MAIN MEASURES: PTSD Checklist-Civilian Version (PCL-C); Neurobehavioral Symptom Inventory (NSI); Ohio State University TBI Identification Method; Patient Health Questionnaire-9 (PHQ-9); Simoa-measured concentrations of tau, amyloid-beta (Aβ) 40, Aβ42, and neurofilament light (NFL). RESULTS: Controlling for age, sex, time since last injury (TSLI), and antianxiety/depression medication use, NFL was trending toward being significantly elevated in participants who had sustained 3 or more TBIs compared with those who had sustained 1 or 2 TBIs. Within the TBI group, partial correlations that controlled for age, sex, TSLI, and antianxiety/depression medication use showed that tau concentrations were significantly correlated with greater symptom severity, as measured with the NSI, PCL, and PHQ-9. CONCLUSIONS: Elevations in tau are associated with symptom severity after TBI, while NFL levels are elevated in those with a history of repetitive TBIs and in military personnel and veterans. This study shows the utility of measuring biomarkers chronically postinjury. Furthermore, there is a critical need for studies of biomarkers longitudinally following TBI.
OBJECTIVE: To understand the relationships between traumatic brain injury (TBI), blood biomarkers, and symptoms of posttraumatic stress disorder (PTSD), depression, and postconcussive syndrome symptoms. DESIGN: Cross-sectional cohort study using multivariate analyses. PARTICIPANTS: One hundred nine military personnel and veterans, both with and without a history of TBI. MAIN MEASURES: PTSD Checklist-Civilian Version (PCL-C); Neurobehavioral Symptom Inventory (NSI); Ohio State University TBI Identification Method; Patient Health Questionnaire-9 (PHQ-9); Simoa-measured concentrations of tau, amyloid-beta (Aβ) 40, Aβ42, and neurofilament light (NFL). RESULTS: Controlling for age, sex, time since last injury (TSLI), and antianxiety/depression medication use, NFL was trending toward being significantly elevated in participants who had sustained 3 or more TBIs compared with those who had sustained 1 or 2 TBIs. Within the TBI group, partial correlations that controlled for age, sex, TSLI, and antianxiety/depression medication use showed that tau concentrations were significantly correlated with greater symptom severity, as measured with the NSI, PCL, and PHQ-9. CONCLUSIONS: Elevations in tau are associated with symptom severity after TBI, while NFL levels are elevated in those with a history of repetitive TBIs and in military personnel and veterans. This study shows the utility of measuring biomarkers chronically postinjury. Furthermore, there is a critical need for studies of biomarkers longitudinally following TBI.
Authors: Lynnette A Averill; Chadi G Abdallah; Robert H Pietrzak; Christopher L Averill; Steven M Southwick; John H Krystal; Ilan Harpaz-Rotem Journal: Chronic Stress (Thousand Oaks) Date: 2017-08-22
Authors: Eric Peter Thelin; Frederick Adam Zeiler; Ari Ercole; Stefania Mondello; András Büki; Bo-Michael Bellander; Adel Helmy; David K Menon; David W Nelson Journal: Front Neurol Date: 2017-07-03 Impact factor: 4.003
Authors: Jonathan E Elliott; Allison T Keil; Sara Mithani; Jessica M Gill; Maya E O'Neil; Akiva S Cohen; Miranda M Lim Journal: Front Syst Neurosci Date: 2022-05-04
Authors: Vivian A Guedes; Rael T Lange; Sara M Lippa; Chen Lai; Kisha Greer; Sara Mithani; Christina Devoto; Katie A Edwards; Chelsea L Wagner; Carina A Martin; Angela E Driscoll; Megan M Wright; Kelly C Gillow; Samantha M Baschenis; Tracey A Brickell; Louis M French; Jessica M Gill Journal: Sci Rep Date: 2022-03-07 Impact factor: 4.379
Authors: Dilorom Sass; Vivian A Guedes; Ethan G Smith; Rany Vorn; Christina Devoto; Katie A Edwards; Sara Mithani; James Hentig; Chen Lai; Chelsea Wagner; Kerri Dunbar; David R Hyde; Leorey Saligan; Michael J Roy; Jessica Gill Journal: Front Pharmacol Date: 2021-11-26 Impact factor: 5.810
Authors: Jonathan E Elliott; Alisha A McBride; Nadir M Balba; Stanley V Thomas; Cassandra L Pattinson; Benjamin J Morasco; Andrea Wilkerson; Jessica M Gill; Miranda M Lim Journal: PLoS One Date: 2022-04-14 Impact factor: 3.752
Authors: Sima Azizi; Daniel B Hier; Blaine Allen; Tayo Obafemi-Ajayi; Gayla R Olbricht; Matthew S Thimgan; Donald C Wunsch Journal: Front Neurol Date: 2021-07-06 Impact factor: 4.003